

# Adele K Fielding

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4668018/publications.pdf>

Version: 2024-02-01

126  
papers

9,672  
citations

94269

37  
h-index

37111

96  
g-index

130  
all docs

130  
docs citations

130  
times ranked

9145  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study. <i>Leukemia</i> , 2022, 36, 625-636.	3.3	25
2	JAK-ing up treatment for CRLF2-R ALL. <i>Blood</i> , 2022, 139, 645-646.	0.6	1
3	In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial. <i>Lancet Haematology</i> , 2022, 9, e276-e288.	2.2	12
4	Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial. <i>Lancet Haematology</i> , 2022, 9, e262-e275.	2.2	14
5	Antibody responses to SARS-CoV-2 vaccination in patients with acute myeloid leukaemia and high risk MDS on active anti-cancer therapies. <i>British Journal of Haematology</i> , 2022, 198, 478-481.	1.2	3
6	Utility of 18F-FDG-PET/CT in lymphoblastic lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1010-1012.	0.6	2
7	Molecular classification improves risk assessment in adult BCR-ABL1 negative B-ALL. <i>Blood</i> , 2021, 138, 948-958.	0.6	59
8	Single nucleotide polymorphism array-based signature of low hypodiploidy in acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 604-615.	1.5	12
9	IKZF1 alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trial. <i>Blood Advances</i> , 2021, 5, 3322-3332.	2.5	7
10	First Analysis of the UKALL14 Randomized Trial to Determine Whether the Addition of Nelarabine to Standard Chemotherapy Improves Event Free Survival in Adults with T-Cell Acute Lymphoblastic Leukaemia (CRUK/09/006). <i>Blood</i> , 2021, 138, 366-366.	0.6	12
11	Inotuzumab ozogamicin versus FLAG-Ida in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia – real-world resource use data. <i>Leukemia and Lymphoma</i> , 2020, 61, 491-493.	0.6	2
12	CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy. <i>Blood Advances</i> , 2020, 4, 4665-4668.	2.5	11
13	Monitoring MRD in ALL: Methodologies, technical aspects and optimal time points for measurement. <i>Seminars in Hematology</i> , 2020, 57, 142-148.	1.8	20
14	Quality-of-life issues and symptoms reported by patients living with haematological malignancy: a qualitative study. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072095500.	1.1	12
15	Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO. <i>Frontiers in Pharmacology</i> , 2020, 11, 571066.	1.6	3
16	Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity. <i>Frontiers in Pharmacology</i> , 2020, 11, 209.	1.6	9
17	Successful remission induction therapy with gilteritinib in a patient with de novo FLT3 mutated acute myeloid leukaemia and severe COVID-19. <i>British Journal of Haematology</i> , 2020, 190, e189-e191.	1.2	17
18	Type 1 Interferon Responses Underlie Tumor-Selective Replication of Oncolytic Measles Virus. <i>Molecular Therapy</i> , 2020, 28, 1043-1055.	3.7	18

#	ARTICLE	IF	CITATIONS
19	Editorsâ€™ Introduction to special issue. British Journal of Haematology, 2020, 191, 519-520.	1.2	1
20	Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study. Frontiers in Pharmacology, 2020, 11, 1308.	1.6	7
21	Acute lymphoblastic leukaemia (ALL) things come to those who wait: 60Âyears of progress in the treatment of adult ALL. British Journal of Haematology, 2020, 191, 558-561.	1.2	1
22	Comparative analysis of melphalan <i>versus</i> busulphan Tâ€cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemia. British Journal of Haematology, 2019, 187, e20-e24.	1.2	3
23	Activated stromal cells transfer mitochondria to rescue acute lymphoblastic leukemia cells from oxidative stress. Blood, 2019, 134, 1415-1429.	0.6	148
24	Oncolytic Measles Virotherapy and Opposition to Measles Vaccination. Mayo Clinic Proceedings, 2019, 94, 1834-1839.	1.4	9
25	Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence study. Journal of Comparative Effectiveness Research, 2019, 8, 523-533.	0.6	12
26	En-Abl-ing treatment of â€Ph-likeâ€ALL?. Blood, 2019, 134, 1277-1278.	0.6	1
27	Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Blood Advances, 2019, 3, 3033-3037.	2.5	16
28	Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2019, 54, 798-809.	1.3	106
29	Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies. Human Vaccines and Immunotherapeutics, 2019, 15, 594-602.	1.4	23
30	Single Nucleotide Polymorphism Array-Based Signature of Genetic Ploidy Groups in Acute Lymphoblastic Leukemia. Blood, 2019, 134, 1473-1473.	0.6	1
31	First Analysis of the UKALL14 Phase 3 Randomised Trial to Determine If the Addition of Rituximab to Standard Induction Chemotherapy Improves EFS in Adults with Precursor B-ALL (CRUK/09/006). Blood, 2019, 134, 739-739.	0.6	11
32	Prognostic Impact of Chromosomal Abnormalities and Copy Number Alterations Among Adults with B-Cell Precursor Acute Lymphoblastic Leukaemia Treated on UKALL14. Blood, 2019, 134, 288-288.	0.6	6
33	Genetic and Genomic Characterisation of Older Adults with Acute Lymphoblastic Leukemia Treated on the UKALL14 and UKALL60+ Clinical Trials. Blood, 2019, 134, 2746-2746.	0.6	1
34	Utility of FDG-PET/CT in Lymphoblastic Lymphoma. Blood, 2019, 134, 2890-2890.	0.6	2
35	Final Development of the First Generic Quality of Life and Symptoms Measure Specific for Hematological Malignancies: The HM-PRO. Blood, 2019, 134, 3484-3484.	0.6	1
36	Whole Genome Profiling of Adult B-Other Acute Lymphoblastic Leukaemia on the UKALL14 Trial. Blood, 2019, 134, 2743-2743.	0.6	0

#	ARTICLE	IF	CITATIONS
37	ARF way to Ph+ ALL stratification?. Blood, 2018, 131, 1394-1395.	0.6	0
38	Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency. Blood, 2018, 131, 917-931.	0.6	68
39	JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia. Journal of Experimental Medicine, 2018, 215, 1929-1945.	4.2	22
40	Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia. Molecular Cancer Therapeutics, 2018, 17, 1739-1751.	1.9	87
41	Commonly Used Chemotherapy Drugs Differentially Determine Microenvironment-Mediated Protection, Via Mitochondrial Transfer, to B-Precursor Acute Lymphoblastic Leukaemia Cells. Blood, 2018, 132, 2690-2690.	0.6	0
42	Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia. Blood, 2017, 129, 3221-3226.	0.6	61
43	Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2017, 376, 836-847.	13.9	1,443
44	Characterisation of the genomic landscape of <i>CRLF2</i> -rearranged acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2017, 56, 363-372.	1.5	49
45	Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. Journal of Clinical Oncology, 2017, 35, 1795-1802.	0.8	348
46	International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica, 2016, 101, 1524-1533.	1.7	154
47	65. Oncolytic Measles Virus Differentially Affects Mitochondrial Biogenesis in Transformed versus Non-Transformed BM-Derived MSCs. Molecular Therapy, 2016, 24, S28-S29.	3.7	0
48	663. Can Oncolytic Measles Virus Targeted to CD20 Recapitulate Any of the Effects of Rituximab in the Treatment of Acute Lymphoblastic Leukemia?. Molecular Therapy, 2016, 24, S262-S263.	3.7	0
49	Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. American Journal of Hematology, 2016, 91, 1107-1112.	2.0	7
50	Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nature Communications, 2016, 7, 13331.	5.8	218
51	Impact of Pretransplantation 18 F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2016, 22, 1234-1241.	2.0	26
52	The Role of Neutrophils in Measles Virus-mediated Oncolysis Differs Between B-cell Malignancies and Is Not Always Enhanced by G-CSF. Molecular Therapy, 2016, 24, 184-192.	3.7	12
53	Development of a Novel Patient-Reported Outcome Measure in Haematological Malignancy for Use in Routine Clinical Practice: Item Generation. Blood, 2016, 128, 5985-5985.	0.6	6
54	Successful Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation in Adults with Inherited Primary Immunodeficiency (PID). Blood, 2016, 128, 4681-4681.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Activation of the LMO2 Oncogene in T-ALL through a Somatically Acquired Neomorphic Promoter. <i>Blood</i> , 2016, 128, 733-733.	0.6	0
56	Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 57-66.	5.1	1,081
57	Delays in Intensification are Common in Adults with Acute Lymphoblastic Leukemia (ALL), are Associated with Decreased Survival in Allogeneic Hematopoietic Cell Transplant (HCT) Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S176-S177.	0.2	0
58	High Frequency and Poor Outcome of Ph-like Acute Lymphoblastic Leukemia in Adults. <i>Blood</i> , 2015, 126, 2618-2618.	0.6	5
59	Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA). <i>Blood</i> , 2015, 126, 679-679.	0.6	39
60	Fludarabine, Melphalan and Alemtuzumab Conditioned Reduced Intensity (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults Aged >40 Years with De Novo Acute Lymphoblastic Leukemia: A Prospective Study from the UKALL14 Trial (ISRCTN 66541317). <i>Blood</i> , 2015, 126, 733-733.	0.6	9
61	in Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukemia, Late Relapses Are Not Uncommon, Occur Mostly in Patients at Standard Risk and Have a Relatively Favorable Outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993. <i>Blood</i> , 2015, 126, 795-795.	0.6	0
62	Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity. <i>Blood</i> , 2014, 123, 1327-1335.	0.6	63
63	<i>IGH</i>@ Translocations Are Prevalent in Teenagers and Young Adults With Acute Lymphoblastic Leukemia and Are Associated With a Poor Outcome. <i>Journal of Clinical Oncology</i> , 2014, 32, 1453-1462.	0.8	87
64	UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. <i>Blood</i> , 2014, 123, 843-850.	0.6	321
65	Mouse xenograft modeling of human adult acute lymphoblastic leukemia provides mechanistic insights into adult LIC biology. <i>Blood</i> , 2014, 124, 96-105.	0.6	24
66	An Evaluation of Molecular Response in a Phase 2 Open-Label, Multicenter Confirmatory Study in Patients (pts) with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Receiving Treatment with the BiTE <sup>®</sup> Antibody Construct Blinatumomab. <i>Blood</i> , 2014, 124, 3704-3704.	0.6	6
67	SSBP2-CSF1R Is a Recurrent Fusion in B-Other Acute Lymphoblastic Leukaemia with Variable Clinical Outcome. <i>Blood</i> , 2014, 124, 3773-3773.	0.6	5
68	Allogeneic Hematopoietic Stem Cell Transplantation Following Anti-CD19 BiTE <sup>®</sup> Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2014, 124, 965-965.	0.6	6
69	Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 7005-7005.	0.8	12
70	Pre-Transplantation FDG-PET Predicts Early but Not Late Survival Outcomes Following Allogeneic Transplantation in Chemo-Sensitive Hodgkin Lymphoma. <i>Blood</i> , 2014, 124, 1225-1225.	0.6	1
71	Delays in Start of Intensification Therapy Are Common for Adults with Acute Lymphoblastic Leukemia, and Are Associated with Decreased Survival in Patients Who Undergo Allogeneic Stem Cell Transplant (SCT). <i>Blood</i> , 2014, 124, 208-208.	0.6	1
72	TP53 Alterations Are Frequent in Patients over 60 Years with B-Precursor Acute Lymphoblastic Leukemia (ALL) and Low Hypodiploid/Near Triploid (HoTr) Karyotype; They Correlate with RB1 Deletion and Leukemic Telomere Gain. <i>Blood</i> , 2014, 124, 3801-3801.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2013, 160, 640-648.	1.2	33
74	The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial. <i>Haematologica</i> , 2013, 98, 945-952.	1.7	54
75	Feasibility Of Pegylated-Asparaginase (PEG-ASP) During Induction In Adults With Acute Lymphoblastic Leukaemia (ALL): Results From The UK Phase 3 Multicentre Trial UKALL 14. <i>Blood</i> , 2013, 122, 3900-3900.	0.6	9
76	Evaluation Of IKZF1 4-7 Deletion As a Suitable Marker For Minimal Residual Disease Monitoring; A Study Of 161 Consecutive Acute Lymphoblastic Leukaemia (ALL) Patients On The On-Going UKALL14 Trial. <i>Blood</i> , 2013, 122, 1335-1335.	0.6	0
77	Barriers To Clinical Trial Enrolment For Teenagers and Young Adults With Acute Lymphoblastic Leukaemia: The Impact of Age Eligibility Criteria. <i>Blood</i> , 2013, 122, 1401-1401.	0.6	0
78	An Optimised In Vivo Modelling System For Adult Acute Lymphoblastic Leukaemia (ALL) Enables Sensitive Detection Of Leukaemia Initiating Cells (LIC) and Drug Resistant Clones. <i>Blood</i> , 2013, 122, 2641-2641.	0.6	1
79	IGH Translocations, CRLF2 Deregulation, and Microdeletions in Adolescents and Adults With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 3100-3108.	0.8	120
80	Attenuated, Oncolytic, but Not Wild-Type Measles Virus Infection Has Pleiotropic Effects on Human Neutrophil Function. <i>Journal of Immunology</i> , 2012, 188, 1002-1010.	0.4	20
81	Recent Developments in the Management of T-Cell Precursor Acute Lymphoblastic Leukemia/Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 160-169.	1.2	10
82	Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. <i>British Journal of Haematology</i> , 2012, 157, 463-471.	1.2	161
83	Biology and Outcome of 85 Adults with Acute Lymphoblastic Leukemia (ALL) with t(4;11)/MLL-AF4 Treated in the UKALL XII/ECOG 2993 Study. <i>Blood</i> , 2012, 120, 663-663.	0.6	0
84	Philadelphia-Positive Acute Lymphoblastic Leukemia—Is Bone Marrow Transplant Still Necessary?. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S84-S88.	2.0	12
85	Donor Lymphocyte Infusions Modulate Relapse Risk in Mixed Chimeras and Induce Durable Salvage in Relapsed Patients After T-Cell-Depleted Allogeneic Transplantation for Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 971-978.	0.8	117
86	Differential Cytopathology and Kinetics of Measles Oncolysis in Two Primary B-cell Malignancies Provides Mechanistic Insights. <i>Molecular Therapy</i> , 2011, 19, 1034-1040.	3.7	22
87	Positive Pre-Transplantation [18-F] FDG-PET Is Not a Barrier to Successful Allograft Outcomes in Chemosensitive Hodgkin Lymphoma. <i>Blood</i> , 2011, 118, 2016-2016.	0.6	0
88	Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2010, 95, 8-12.	1.7	26
89	Incidence and Dynamics of Epstein-Barr Virus Reactivation After Alemtuzumab-Based Conditioning for Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Transplantation</i> , 2010, 90, 564-570.	0.5	57
90	Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma. <i>Blood</i> , 2010, 115, 2763-2768.	0.6	58



#	ARTICLE	IF	CITATIONS
91	Minimal residual disease is a significant predictor of treatment failure in non Tâ€lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. British Journal of Haematology, 2010, 148, 80-89.	1.2	147
92	Antigen receptor gene rearrangements reflect on the heterogeneity of adult Acute Lymphoblastic Leukaemia (ALL) with implications of cellâ€™origin of ALL subgroups â€™ a UKALLXII study. British Journal of Haematology, 2010, 148, 394-401.	1.2	9
93	HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning. Blood, 2010, 115, 5147-5153.	0.6	56
94	Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial. Blood, 2010, 116, 169-169.	0.6	13
95	Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial. Blood, 2010, 116, 493-493.	0.6	3
96	Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (B-ALL) Patients (pts) From the International UKALLXII/E2993 Trial: No Difference In Results Between B Cell Immunophenotypic Subgroups. Blood, 2010, 116, 524-524.	0.6	6
97	Vaccine Measles Virus Has Therapeutic Potential In B Cell Malignancy.. Blood, 2010, 116, 3757-3757.	0.6	0
98	Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. Haematologica, 2009, 94, 1399-1406.	1.7	34
99	T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood, 2009, 114, 5136-5145.	0.6	346
100	Phase I Study of High-Stringency CD8 Depletion of Donor Leukocyte Infusions After Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation, 2009, 88, 1312-1318.	0.5	23
101	Prospective outcome data on 267 unselected adult patients with Philadelphia chromosomeâ€™positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood, 2009, 113, 4489-4496.	0.6	257
102	Attenuated Measles Virus: A Promising Therapeutic Modality for B Cell Malignancy.. Blood, 2009, 114, 2460-2460.	0.6	0
103	In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood, 2008, 111, 1827-1833.	0.6	702
104	Response: Chemotherapy or allografting for young adults with high-risk ALL?. Blood, 2008, 111, 5755-5755.	0.6	8
105	Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood, 2008, 112, 3314-3314.	0.6	1
106	T-Cell Depleted Unrelated Donor Stem Cell Transplants Appear to Be of Value for Adult Philadelphia Chromosome Negative ALL Patients and Should Be Evaluated Prospectively in New Large Group Studies. Blood, 2008, 112, 4413-4413.	0.6	0
107	Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood, 2007, 109, 3189-3197.	0.6	655
108	Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood, 2007, 109, 944-950.	0.6	716

#	ARTICLE	IF	CITATIONS
109	Be careful what you wish for?. <i>Blood</i> , 2007, 109, 2673-2674.	0.6	0
110	Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. <i>Nature</i> , 2007, 447, 966-971.	13.7	355
111	Does Imatinib Change the Outcome in Philadelphia Chromosome Positive Acute Lymphoblastic Leukaemia in Adults? Data from the UKALLXII/ECOG2993 Study.. <i>Blood</i> , 2007, 110, 8-8.	0.6	22
112	In Adults with Standard-Risk Acute Lymphoblastic Leukemia (ALL) the Greatest Benefit Is Achieved from an Allogeneic Transplant in First Complete Remission (CR) and an Autologous Transplant Is Less Effective Than Conventional Consolidation/Maintenance Chemotherapy: Final Results of the International ALL Trial (MRC UKALL XII/ECOG E2993).. <i>Blood</i> , 2006, 108, 2-2.	0.6	8
113	Measles as a potential oncolytic virus. <i>Reviews in Medical Virology</i> , 2005, 15, 135-142.	3.9	38
114	The Value of Molecular Monitoring for Residual Disease (MRD) in Early Morphological Remitters among Adults Diagnosed with B Cell ALL and Treated According to the MRC UKALL12 Protocol.. <i>Blood</i> , 2005, 106, 1467-1467.	0.6	2
115	Molecular Monitoring of Residual Disease (MRD) during Induction and Intensification Phases in Low Risk Adult B Cell ALL Treated According to the MRC UKALL12 Protocol.. <i>Blood</i> , 2005, 106, 1466-1466.	0.6	4
116	Value of Molecular Monitoring for Minimal Residual Disease Preceding Autologous SCT Following Diagnosis of B Cell Acute Lymphoblastic Leukemia in Patients Treated with the MRC UKALL12 Protocol.. <i>Blood</i> , 2005, 106, 1468-1468.	0.6	0
117	Karyotype Is an Independent Prognostic Factor in Adult Acute Lymphoblastic Leukaemia (ALL): Analysis of Cytogenetic Data from 1,235 Patients on the Medical Research Council (MRC) UKALLXII /Eastern Cooperative Oncology Group (ECOG) 2993 Trial.. <i>Blood</i> , 2005, 106, 331-331.	0.6	1
118	The Impact of Imatinib Therapy on Adult Philadelphia Positive Acute Lymphoblastic Leukaemia (ALL): Early Results from the UKALL12/ECOG 2993 Study.. <i>Blood</i> , 2005, 106, 1839-1839.	0.6	2
119	An oncolytic measles virus engineered to enter cells through the CD20 antigen. <i>Molecular Therapy</i> , 2003, 7, 62-72.	3.7	86
120	Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression. <i>Cancer Research</i> , 2003, 63, 6463-8.	0.4	82
121	Strength of Envelope Protein Interaction Modulates Cytopathicity of Measles Virus. <i>Journal of Virology</i> , 2002, 76, 5051-5061.	1.5	111
122	Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. <i>Blood</i> , 2001, 97, 3746-3754.	0.6	223
123	A Hyperfusogenic Gibbon Ape Leukemia Envelope Glycoprotein: Targeting of a Cytotoxic Gene by Ligand Display. <i>Human Gene Therapy</i> , 2000, 11, 817-826.	1.4	51
124	Acquired skewing of X chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age. <i>British Journal of Haematology</i> , 1997, 98, 512-519.	1.2	230
125	G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. <i>British Journal of Haematology</i> , 1997, 99, 933-938.	1.2	70
126	Peripheral Blood Progenitor Cells Versus Bone Marrow. <i>Stem Cells and Development</i> , 1994, 3, 299-304.	1.0	4